Supplementary Table 1. Two different treatment regimens for anti-vascular endothelial growth factor therapy in patients with diabetic macular edema.

| PRN regimen (BCVA and OCT examined at every clinic visit) | Injection | Follow-up only |
|---------------------------------------------------------|-----------|----------------|
|                                                         | BCVA loss ≥ 5 ETDRS letters OR New or increased SRF and/or IRC OR CFT increase ≥ 100 μm | BCVA loss < 5 ETDRS letters AND No SRF and IRC, or stable IRC over 2 consecutive treatment visits after the loading phase AND CFT increase < 100 μm |

| T&E regimen (BCVA and OCT examined at every clinic visit) | Shorten (-4 weeks) | Extend (+4 weeks) |
|---------------------------------------------------------|--------------------|-------------------|
|                                                         | Minimum interval: 4 weeks | Maximum interval: 24 weeks |
|                                                         | BCVA loss ≥ 5 ETDRS letters OR New or increased SRF and/or IRC OR CFT increase ≥ 100 μm | BCVA loss < 5 ETDRS letters AND No SRF and IRC, or stable IRC over 2 consecutive treatment visits after the loading phase AND CFT increase < 100 μm |

BCVA, best-corrected visual acuity; CFT, central foveal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; IRC, intraretinal cyst; OCT, optical coherence tomography; PRN, pro re nata; SRF, subretinal fluid; T&E, treat-and-extend.